POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
Isotopia to supply POINT with no-carrier-added Lu-177 for use in POINT’s Indianapolis, IN radioligand production facility
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”. Gross proceeds from the transaction totaled approximately $286.7 million.
POINT announced today the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs ...